In Brief: Dade Behring
This article was originally published in The Gray Sheet
Executive Summary
Dade Behring: Diagnostic firm broadens its immunosuppressive drug monitoring menu by licensing from Abbott rights to develop a test to monitor for Fujisawa's Prograf FK506 (tacrolimus). Dade Behring initially plans to incorporate the test into its Emit 2000 immunochemistry analyzer. Dade Behring's Emit platform currently includes a test to monitor the levels of cyclosporine in kidney, heart and liver transplant patients. The company also plans to offer for research use an assay to measure in plasma levels of mycophenolic acid (MPA), the active form of Roche's drug CellCept, which is used with FK506 and cyclosporine to prevent organ transplant rejection...